LiberiaTuberculosis profile
Population  2017 4.7 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.7 (1.6–4.1) 57 (34–86)
Mortality (HIV+TB only) 0.91 (0.57–1.3) 19 (12–28)
Incidence  (includes HIV+TB) 15 (9.4–21) 308 (199–440)
Incidence (HIV+TB only) 2.2 (1.4–3.2) 47 (30–68)
Incidence (MDR/RR-TB)** 0.39 (0.15–0.74) 8.3 (3.2–16)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.91 (0.82–0.99) 4.6 (3.6–5.7) 5.5 (4.2–6.9)
Males 1 (0.9–1.1) 8 (5.7–10) 9 (6.3–12)
Total 1.9 (1.6–2.2) 13 (8.1–17) 15 (9.4–21)
TB case notifications, 2017  
Total cases notified 7 728
Total new and relapse 7 728
          - % tested with rapid diagnostics at time of diagnosis 17%
          - % with known HIV status 70%
          - % pulmonary 68%
          - % bacteriologically confirmed among pulmonary 64%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 53% (37–82)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.26 (0.14–0.4)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 827 15%
          - on antiretroviral therapy 347 42%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  150
(65–230)
Estimated % of TB cases with MDR/RR-TB 2.5% (1.1–4.3) 14% (10–18)  
% notified tested for rifampicin resistance 43% 100% 3 382
MDR/RR-TB cases tested for resistance to second-line drugs   19
Laboratory-confirmed cases MDR/RR-TB: 88, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 55, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 77% 7 374
Previously treated cases, excluding relapse, registered in 2016 50% 127
HIV-positive TB cases registered in 2016    
MDR/RR-TB cases started on second-line treatment in 2015    
XDR-TB cases started on second-line treatment in 2015    
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
5.8% (5.3–6.3)
TB financing, 2018  
National TB budget (US$ millions) 6.4
Funding source: 2% domestic, 98% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-11-21 Data: www.who.int/tb/data